 

Chemed Corporation reported its third quarter 2020 operating results, which showed sequential improvement starting in May 2020 and accelerating throughout the third quarter. The hospice segment operations were impacted by the pandemic, but the federal government's support allowed the company to generate operational improvement. Roto-Rooter services demand began to show weekly improvement in the second and third quarters of 2020, and its unit-for-unit commercial revenue declined 11.6% in the third quarter when compared to the prior year quarter, which was a significant improvement from the 29.1% decline in the second quarter 2020 commercial revenue. VITAS' full year 2020 adjusted EBITDA margin prior to Medicare Cap is estimated to be 21%, and Roto-Rooter is forecasted to achieve full year 2020 revenue growth of 12.5% to 13%. Chemed's full year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits for stock options, costs related to litigation and other discrete items, is estimated to be in the range of $18 to $18.15. The company's average daily census in 2020 is estimated to expand approximately 1.3%, and Medicare Cap billing limitations for calendar year 2020 are estimated to be $8.6 million.